Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009

Shigella is becoming an increasing public health problem due to development of multiple antimicrobial resistance, frequently resulting in treatment failure. A systematic review was conducted based on a literature search of computerised databases. Random or fixed-effects models were used, based on th...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2012-07, Vol.40 (1), p.9-17
Main Authors: Gu, Bing, Cao, Yan, Pan, Shiyang, Zhuang, Ling, Yu, Rongbin, Peng, Zhihang, Qian, Huimin, Wei, Yongyue, Zhao, Lianying, Liu, Genyan, Tong, Mingqing
Format: Article
Language:English
Subjects:
Africa - epidemiology
Americas - epidemiology
Anti-Bacterial Agents - pharmacology
antibiotic resistance
Antibiotics. Antiinfectious agents. Antiparasitic agents
Asia - epidemiology
Biological and medical sciences
Ciprofloxacin
Ciprofloxacin - pharmacology
confidence interval
Drug Resistance, Bacterial
Dysentery, Bacillary - epidemiology
Dysentery, Bacillary - microbiology
Europe - epidemiology
Humans
Infectious Disease
Medical sciences
Meta-analysis
monitoring
Nalidixic acid
Nalidixic Acid - pharmacology
Pharmacology. Drug treatments
Prevalence
public health
Resistance
Shigella flexneri
Shigella flexneri - drug effects
Shigella flexneri - isolation & purification
Shigella sonnei
Shigella sonnei - drug effects
Shigella sonnei - isolation & purification
statistical analysis
systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Shigella is becoming an increasing public health problem due to development of multiple antimicrobial resistance, frequently resulting in treatment failure. A systematic review was conducted based on a literature search of computerised databases. Random or fixed-effects models were used, based on the P-value considering the possibility of heterogeneity between studies, for meta-analysis. Statistical analyses were performed using STATA 10.0. In the area of Asia–Africa, resistance rates to nalidixic acid and ciprofloxacin were 33.6% [95% confidence interval (CI) 21.8–46.6%] and 5.0% (95% CI 2.8–7.8%), respectively, 10.5 and 16.7 times those of Europe–America. Moreover, resistance to nalidixic acid and ciprofloxacin in Asia–Africa progressively increased each year, reaching 64.5% (95% CI 13.8–99.3%) and 29.1% (95% CI 0.9–74.8%), respectively, in 2007–2009, whilst isolates in Europe–America remained at low levels of resistance (
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2012.02.005